#1leading
Pyrin gain-of-function mutations lower the activation threshold of the pyrin inflammasome by impairing phosphorylation-dependent inhibition
50 studies·pathogenesis
90
evidence
Familial Mediterranean Fever
Also known asFMFFamilial Paroxysmal PolyserositisPeriodic Disease
Familial Mediterranean Fever (FMF) is the most common monogenic autoinflammatory disease worldwide, caused by gain-of-function mutations in the MEFV gene encoding pyrin. It is characterized by recurrent self-limited episodes of fever and serositis (peritonitis, pleuritis, synovitis) lasting 1-3 days, predominantly affecting populations of Mediterranean descent.
Data sourced from 36 published studies with evidence grading (A–D). Last reviewed . Not medical advice.
Pathophysiology✓Well understood
Treatment✓Effective treatment available
Genetic basis✓Well characterized
Research activity
36 studies·0 active trials·1974–2025
Epidemiology
- Total cases
- Unknown
- Mean onset
- 10 years
- Onset range
- 1–40 years
- Sex ratio (M:F)
- 1.2:1
- Diagnostic delay
- ~7 years
- Discovered
- 1945 (Sheppard Siegal)
- Prevalence
- 1-5/10,000 (up to 1/200 in high-risk populations)
- Classification
- Autoinflammatory, Monogenic
Cardinal Features
8 key symptoms and signs
| Feature | Frequency | Category | Sources |
|---|---|---|---|
Recurrent fever Fever typically 38-40C, lasting 12-72 hours. Self-limited. Occurs with attacks of serositis. Attack frequency ranges from several times per week to once per year. | 93% | systemic | |
Peritonitis (abdominal pain) Sterile peritonitis with acute abdominal pain mimicking surgical abdomen. Most common feature — present in 93.7% of Turkish cohort. Pain diffuse or localised, with rebound tenderness. Resolves spontaneously in 1-3 days. Can lead to unnecessary appendectomies. | 94% | gastrointestinal | |
Pleuritis (chest pain) Unilateral pleuritic chest pain, usually sharp and exacerbated by breathing. Present in approximately 31% of patients. Causes small pleural effusions. Resolves within 48 hours. | 31% | respiratory | |
Arthritis / Arthralgia Acute monoarthritis, typically large joints (knee, ankle, hip). Present in 47.4% of Turkish cohort. Significantly more frequent with M694V homozygosity (71%). Can be the sole manifestation. Usually non-destructive but protracted arthritis can cause joint damage. | 47% | musculoskeletal | |
Myalgia Muscle pain present in approximately 39.6% of patients. Can manifest as exercise-induced myalgia or febrile myalgia syndrome. Protracted febrile myalgia is a severe variant lasting weeks. | 40% | musculoskeletal | |
Elevated acute phase reactants (CRP, ESR, SAA) Massively elevated CRP, ESR, and SAA during attacks. Persistent subclinical elevation between attacks indicates ongoing inflammation and risk for amyloidosis. SAA is the most sensitive marker for subclinical inflammation. | 95% | laboratory | |
Pericarditis Rare manifestation of FMF-associated serositis. Chest pain with pericardial effusion. Less common than pleuritis or peritonitis. | 1% | cardiovascular | |
Acute scrotal inflammation Acute scrotal pain and swelling due to inflammation of the tunica vaginalis. More common in children. Can mimic testicular torsion, leading to unnecessary surgery. | 5% | genitourinary |
Hypothesis Tracker
Competing explanations ranked by evidence weight
#2leading
Subclinical inflammation between attacks, not the attacks themselves, is the primary driver of long-term complications including AA amyloidosis
30 studies·clinical
75
evidence
#3leading
Colchicine works in FMF primarily through anti-inflammatory effects on leukocyte function rather than direct pyrin inflammasome inhibition
20 studies·treatment_mechanism
70
evidence
#4leading
High carrier frequency of MEFV mutations reflects heterozygote advantage against intracellular pathogens, particularly Yersinia pestis
15 studies·evolutionary_genetics
65
evidence
#5emerging
FMF heterozygotes can manifest clinical disease through a pseudo-dominant or dose-dependent mechanism involving gene modifiers and environmental triggers
25 studies·genetics
50
evidence
Open Questions
Why do up to 25% of clinically confirmed FMF patients have only one identifiable MEFV mutation?
Standard genetic testing covers exons 2, 3, 5, and 10. Second mutations may reside in regulatory regions, deep intronic sequences, or involve structural variants not detected by current methods. Alternatively, single-allele disease may represent a genuine pseudo-dominant mechanism.
What is the exact mechanism by which colchicine prevents FMF attacks despite mutant pyrin being insensitive to microtubule disruption?
Van Gorp et al. 2016 showed FMF mutations lift the obligatory requirement for microtubules in pyrin inflammasome activation, yet colchicine is ~95% effective clinically. The leading hypothesis involves leukocyte motility and phagocytosis, but the precise molecular targets are unclear.
Can biomarkers predict which patients will develop AA amyloidosis despite colchicine treatment?
AA amyloidosis remains the most feared complication. Known risk factors include M694V homozygosity, SAA1 alpha/alpha genotype, and persistently elevated SAA. However, some compliant patients still develop amyloidosis, and there is no validated predictive model.
What are the optimal treatment strategies for colchicine-resistant FMF beyond IL-1 blockade?
5-10% of FMF patients are colchicine-resistant and some fail IL-1 blockers as well. JAK inhibitors (tofacitinib) and IL-6 blockade (tocilizumab) are emerging options, but evidence is limited to case series and one phase III trial. No head-to-head comparisons exist.
Does heterozygote advantage against Yersinia pestis or other pathogens fully explain the high MEFV carrier frequencies?
Carrier rates of 1:3.5-5 in Mediterranean populations are remarkably high for a recessive disease. Mouse studies show FMF mutations confer Yersinia resistance, but human evidence is lacking. Genetic drift in founder populations is an alternative explanation.
What triggers individual FMF attacks in patients with stable underlying genetic susceptibility?
Attack frequency varies widely (several per week to once per year) and individual attacks appear to be triggered by environmental factors including stress, exercise, menstruation, and infections. The molecular link between these triggers and pyrin inflammasome activation is unknown.
Recent Updates
IL-1 blockade established as standard second-line therapy for colchicine-resistant FMF
Meta-analysis by Grattagliano et al. (2023) and updated EULAR/PReS 2024 recommendations confirm anti-IL-1 agents (anakinra, canakinumab) significantly reduce attack frequency and inflammatory markers in colchicine-resistant FMF. Both anakinra and canakinumab show high efficacy with complete response rates of 67-77%.
EULAR/PReS 2024 updated management recommendations published
Ozen et al. published the 2024 update to EULAR recommendations for FMF management, including 4 overarching principles and 12 specific recommendations. Colchicine should be initiated immediately upon clinical diagnosis. IL-1 inhibitors recommended for inadequate colchicine response. Colchicine confirmed safe in pregnancy.
Colchicine resistance mechanisms linked to pyrin inflammasome microtubule independence
Building on Van Gorp et al. (2016) findings, ongoing research clarifies that FMF mutations render pyrin inflammasome activation independent of microtubules, explaining why colchicine — a microtubule disruptor — fails in some patients. Colchicine's clinical efficacy likely operates through leukocyte motility and adhesion rather than direct inflammasome inhibition.
SAA1 gene polymorphisms identified as independent amyloidosis risk modifier
The SAA1 alpha/alpha genotype has been confirmed as an independent risk factor for AA amyloidosis in FMF, beyond MEFV genotype alone. Patients with both M694V homozygosity and SAA1 alpha/alpha genotype face the highest amyloidosis risk, supporting genotype-guided monitoring strategies.
MEFV variant reclassification efforts underway
Systematic review by Shinar et al. highlighted the lack of univocal genotype-phenotype correlation in FMF. Ongoing international efforts aim to reclassify MEFV variants using updated ACMG criteria, particularly for E148Q (debated as pathogenic vs. benign polymorphism) and heterozygous states that may cause mild disease.
JAK inhibitors (tofacitinib) emerging as potential third-line therapy
Multiple independent case series (2024-2025) report that tofacitinib, a JAK1/3 inhibitor, achieves marked suppression of inflammation and sustained remission in FMF patients resistant to both colchicine and IL-1 blockade. Larger controlled studies are needed to establish efficacy and safety.
FMF mutations confer resistance to Yersinia pestis — heterozygote advantage confirmed
Park et al. (2020, Nat Immunol) demonstrated that FMF-associated pyrin mutations provide enhanced resistance to Yersinia pestis virulence factors. This explains the remarkably high carrier frequencies (1 in 3.5 to 1 in 5) in Mediterranean populations through positive evolutionary selection.
Canakinumab FDA-approved for FMF (CLUSTER trial)
In 2016, canakinumab became the first FDA-approved biologic for colchicine-resistant FMF based on the pivotal CLUSTER trial. The trial demonstrated that canakinumab achieved complete control of disease flares in 61% of FMF patients versus 6% with placebo, establishing IL-1 blockade as an evidence-based second-line therapy.
Global FMF registry reveals declining amyloidosis incidence with early colchicine
Data from the international Eurofever/PRINTO registry covering over 2,800 FMF patients showed that AA amyloidosis incidence has dropped from 15-20% historically to under 2% in patients who start colchicine early. This reinforces the importance of prompt diagnosis and lifelong colchicine adherence.
Pyrin inflammasome structural mechanism fully elucidated
Structural biology studies resolved the pyrin inflammasome filament architecture, showing how FMF-associated MEFV mutations destabilize the autoinhibitory interaction between the pyrin SPRY domain and the B30.2 domain. This explained why gain-of-function mutations constitutively activate the inflammasome and provided a structural basis for rational drug design targeting pyrin.